Anlotinib-induced sick sinus syndrome:Two case reports  

作　　者：Cheng-Feng Fu Li-Fen Yang Lei Tian Song Deng Qi Zhang Biao Yao 

机构地区：[1]Department of Oncology,Tongren People’s Hospital,Tongren 554300,Guizhou Province,China [2]Department of Oncology,Guizhou Provincial People’s Hospital,Guiyang 550000,Guizhou Province,China

出　　处：《World Journal of Clinical Cases》2025年第6期30-34,共5页世界临床病例杂志（英文）

摘　　要：BACKGROUND This manuscript describes the first known cases of sick sinus syndrome(SSS)associated with the use of anlotinib in non-small cell lung cancer patients,highlighting the need for increased vigilance and cardiac monitoring.CASE SUMMARY Two patients with non-small cell lung cancer developed SSS after 15 months and 5 months of anlotinib treatment,respectively,presenting with syncope and palpit-ations.Electrocardiogram confirmed SSS,and different treatment approaches were taken for each patient.One patient received a dual-chamber permanent pacemaker,while the other discontinued the medication and experienced symptom resolution.CONCLUSION Anlotinib can induce SSS,suggesting that cardiac monitoring is crucial during anlotinib treatment.Individualized management strategies are necessary for affected individuals.

关 键 词：Lung cancer Anlotinib Sick sinus syndrome Cardiac pacemaker Adverse drug reaction Case report 

分 类 号：R692.6[医药卫生—泌尿科学]